Drug Research

Fuatilia

GLP-1 Drugs Halve Cardiac Risk

Recent research showed that GLP-1 receptor agonists reduce cardiac event risks by half in certain patient groups. This finding supports expanded use of these drugs beyond diabetes management. The study contributes to ongoing discussions in cardiovascular medicine.

Tovuti hii inatumia vidakuzi

Tunatumia vidakuzi kwa uchambuzi ili kuboresha tovuti yetu. Soma sera ya faragha yetu kwa maelezo zaidi.
Kataa